Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Potential Governing Body Emerges For DSCSA Tracing Of US-Marketed Drug Packages

Executive Summary

The idea of establishing a non-profit governance group to coordinate the package-level tracing of pharmaceuticals through the US distribution chain that DSCSA requires drew widespread support at a May 1 PDSA meeting in Washington, DC. PDSA wants to get the group up and running by October.

You may also be interested in...



New DSCSA Track And Trace Governing Body Up And Running

Despite some previous uncertainty about sufficient funding commitments from members, the coalition of manufacturers, wholesalers and distributors is operational, with a meeting planned for early next year. It will oversee data governance systems for implementing the US supply chain safety law, a key element of the law's third phase set to go into effect November 2023.

PDSA Asks Stakeholders To Join DSCSA Track-And-Trace Governing Body By September

But there’s a wrinkle: Many prospective participants cannot budget for the tiered fees until 2020.

FDA Warns Against Using Compounded Remdesivir Due To Quality Concerns

Although compounding of certain shortage drugs is allowed during the public health emergency, remdesivir is off limits due to its complexity. Providers should only use the FDA-approved version of the drug, Gilead’s Veklury, the agency says.

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel